Overview

Ketamine Alcohol (in Treatment-Resistant Depression)

Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
0
Participant gender:
All
Summary
A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD). A family history of an alcohol use disorder (Family History Positive, FHP) is one of the strongest identified predictors of an improved antidepressant response to ketamine. Like ketamine, alcohol is a functional NMDA receptor antagonist. FHP is associated with differential response to both alcohol, e.g. decreased body sway and plasma cortisol, and ketamine, e.g. blunted psychotomimetic side effects. One of the primary mechanistic hypotheses for ketamine's antidepressant action is the acute intrasynaptic release of glutamate from major output neurons, e.g. cortical pyramidal cells. Preliminary clinical studies have demonstrated this acute glutamate "surge" in response to subanesthetic dose ketamine. Based on these findings, the investigators hypothesize that ketamine's enhanced antidepressant efficacy in FHP TRD subjects is, at least in part, attributable to increased glutamate release relative to TRD subjects without a family history of alcohol use disorder (Family History Negative, FHN). The investigators also hypothesize that alcohol similarly augments glutamate release in this bio- logically-enriched subgroup, which may be a more objective biomarker than family history status. To test these hypotheses, the investigators have designed a now two-site, open-label study of 21-65 year old medically and neurologically healthy, currently moderately-to-severely depressed TRD patients. In total, the investigators plan to recruit 25 FHP and 25 FHN TRD subjects. All subjects must not have a lifetime substance use disorder (except nicotine or caffeine), no lifetime history of an alcohol use disorder and socially drink. The experimental portion consists of two phases. The preliminary first phase is a medication taper (if needed) and psychotropic medication-free period. The experimental second phase comprises two pharmacokinetically-defined basal-bolus alcohol and one subanesthetic dose (0.5mg/kg x 40 minute) ketamine infusions. The first alcohol infusion will establish the pharmacokinetic profile for a subsequent alcohol infusion occurring during 7T-magnetic resonance imaging (MRI), both resting-state functional MRI (rs-fMRI) and magnetic resonance spectroscopy (MRS) to detect glutamate in the ventromedial prefrontal cortex/ventral anterior cingulate cortex (vmPFC/vACC). The ketamine infusion will also occur during 7T-MRI. The primary outcome measure is group mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from pre-ketamine infusion (baseline) to one week post-infusion, where the investigators observed ketamine's greatest antidepressant effect in FHP TRD. Additional outcome measures are vmPFC/vACC glutamate change in response to ketamine and alcohol challenge based on family history status. In summary, this study will provide key mechanistic information on ketamine's improved antidepressant efficacy in a biologically-enriched subgroup. This will contribute to the systematic development of more efficacious, personalized treatments for major depression in an effort to reduce its enormous public health burden.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Mark Niciu
National Institute of Mental Health (NIMH)
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Antidepressive Agents
Ethanol
Ketamine
Criteria
INCLUSION CRITERIA:

1. 21 to 65 years of age.

2. A level of understanding sufficient to agree to all required tests and examinations,
sign an informed consent document and verify understanding by a score greater than or
equal to 90% on the consent quiz.

3. Diagnostic and Statistical Manual-4th Edition-Text Revision (DSM-IV-TR)) diagnosis of
major depressive disorder (MDD), single-episode (296.30) or recurrent (296.20) without
psychotic features based on clinical assessment and confirmed by a Structured Clinical
Interview for the DSM-IV- Patient Version (SCID-P). Subjects must be experiencing a
current major depressive episode of at least 2 weeks duration.

4. Past failure of greater than or equal to one standard antidepressant trial based on
the Antidepressant Treatment History Form (ATHF).

5. MADRS score greater than or equal to 20 at baseline and the day of ketamine infusion.

EXCLUSION CRITERIA:

1. Inadequate knowledge of family mental and substance use history, e.g. adoption.

2. Current psychotic features or prior diagnosis of a DSM-IV-TR psychotic spectrum
disorder, e.g. schizophrenia, schizoaffective disorder, bipolar I disorder with
psychotic features, MDD with psychotic features, or bipolar disorder, e.g. bipolar I
disorder without psychotic features, bipolar II disorder and bipolar disorder not
otherwise specified (NOS).

3. Current/active DSM-IV-TR drug or alcohol use disorder (except for caffeine or nicotine
dependence), currently seeking help for alcohol problems, abstinent with a history of
an alcohol use disorder, non-drinkers (no alcohol in the past year), or a history of
alcohol-induced flushing reactions.

4. Pregnant or nursing women or women of child bearing potential not using at least one
medically accepted means of contraception (to include oral, injectable, or implant
birth control, condom or diaphragm with spermicide, intrauterine devices (IUD), tubal
ligation, abstinence or partner with vasectomy).

5. Serious, unstable medical conditions/problems including hepatic, renal,
gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic,
immunologic, or hematologic disease, e.g. uncontrolled asthma, uncontrolled
hyper/hypothyroidism or active cancer.

6. Presence of any medical illness likely to alter brain morphology and/or physiology
(e.g., hypertension, diabetes) even if controlled by medications.

7. Clinically significant abnormal laboratory tests.

8. Subjects with one or more seizures without clear and resolved etiology and head injury
with loss of consciousness for > 5 minutes or requiring hospitalization.

9. Treatment with psychiatric medications, e.g. selective serotonin reuptake inhibitors,
serotonin norepinephrine reuptake inhibitors, benzodiazepines and antipsychotics, at
least two weeks of study phase II.

10. Treatment with fluoxetine within 5 weeks of study phase II.

11. Treatment with device-based treatment for depression, e.g. electroconvulsive therapy
(ECT), transcranial magnetic stimulation (TMS) and vagal nerve stimulation (VNS),
within 4 weeks of study phase II.

12. Lifetime history of deep brain stimulation.

13. Treatment with any disallowed concomitant medications.

14. Positive HIV test

15. Presence of ferromagnetic implants, e.g, heart pacemaker or aneurysm clip, or other
contraindications to magnetic resonance imaging (MRI), e.g. claustrophobia or hearing
loss.

16. Clinically-significant anatomical brain abnormalities detected on routine brain MRI.

17. Subjects who, in the investigator's judgment, pose a current serious suicidal or
homicidal risk, or who have a MADRS item 10 score of greater than or equal to 4.

18. A current NIMH employee/staff or their immediate family member (N.B. former exclusion
criteria likely to be no longer relevant at the University of Iowa Health Care).

19. Currently engaged in an evidence-based structured psychotherapy for mood and/or
anxiety disorders, e.g. cognitive-behavioral therapy (CBT) or interpersonal
psychotherapy (IPT).

Additionally, the investigators may exclude or terminate any patient for clinical reasons.